<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364644">
  <stage>Registered</stage>
  <submitdate>22/07/2013</submitdate>
  <approvaldate>29/07/2013</approvaldate>
  <actrnumber>ACTRN12613000831785</actrnumber>
  <trial_identification>
    <studytitle>A Phase I, Proof of Concept, Open Label, Escalating Dose Study to Assess the Safety, Tolerability and Immunogenicity of a Herpes Simplex Virus (HSV) Deoxyribonucleic Acid (DNA) Vaccine</studytitle>
    <scientifictitle>A Phase I, Proof of Concept, Open Label, Escalating Dose Study to Assess the Safety, Tolerability and Immunogenicity of a Herpes Simplex Virus (HSV) Deoxyribonucleic Acid (DNA) Vaccine in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Genital Herpes</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>HSV-2 DNA Vaccine
There are 5 treatment arms with the first dose being the lowest dose given to Arm 1 and then Arm 2 receives  dose 3x greater than Arm 1 and then Arm 3 receives dose 10x greater than Arm 1 and then Arm 4 receives 30x greater than Arm 1 and then Arm 5 receives 100x greater than Arm 1. Each dose is given intradermally 3 times 3 weeks apart. The subject will be monitored 3 weeks post the last vaccination.</interventions>
    <comparator>Immunological response post vaccination compared to baseline prior to vaccination</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability. The investigator will solicit for adverse events and a diary card will be used by the subjects.</outcome>
      <timepoint>First vaccination until study completion. Monitoring visits will take place 24h and 48h after vaccination and thereafter the subject will keep a diary card for another 5 days. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Antibody response will be measured by ELISA </outcome>
      <timepoint>Antibody titres will be evaluated immediately pre vaccination and 3 weeks post vaccination after completion of dosing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>HSV-1 and 2 seronegative
Generally healthy
No birthmarks, tattoos, wounds or skin conditions on either forearm</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Suffering acute or chronic disease
Pregant or nursing females
HSV, Hepatitis B or C, or HIV seropositive</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures>5 groups receive escalating doses of the vaccine</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>26/08/2013</anticipatedstartdate>
    <actualstartdate>5/08/2013</actualstartdate>
    <anticipatedenddate>30/09/2013</anticipatedenddate>
    <actualenddate>23/09/2013</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Coridon Pty Ltd</primarysponsorname>
    <primarysponsoraddress>PO BOX 6132
BURANDA QLD 4102</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Coridon Pty Ltd</fundingname>
      <fundingaddress>PO BOX 6132
BURANDA QLD 4102</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Safety, Tolerability and Immunogenicity of a HSV DNA Vaccine</summary>
    <trialwebsite />
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>QIMR Human Research Ethics Committee</ethicname>
      <ethicaddress>QIMR Locked Bag 2000
Royal Brisbane and Women's Hospital
Qld 4029</ethicaddress>
      <ethicapprovaldate>21/06/2013</ethicapprovaldate>
      <hrec>P1531</hrec>
      <ethicsubmitdate>14/05/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Paul Griffin</name>
      <address>Q-Pharm Pty Ltd
QIMR-Clive Berghofer Cancer Research Centre
Level 5, 300 Herston Road
Herston QLD 4006</address>
      <phone>+61738453636</phone>
      <fax>+61738453630</fax>
      <email>p.griffin@qpharm.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Neil Finlayson</name>
      <address>Coridon Pty Ltd
PO BOX 6132
BURANDA QLD 4102</address>
      <phone>+61734436996</phone>
      <fax>+61734437779</fax>
      <email>enquiries@coridon.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Neil Finlayson</name>
      <address>Coridon Pty Ltd
PO BOX 6132
BURANDA QLD 4102</address>
      <phone>+61734436996</phone>
      <fax>+61734437779</fax>
      <email>neil.finlayson@coridon.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Neil Finlayson</name>
      <address>Coridon Pty Ltd
PO BOX 6132
BURANDA QLD 4102</address>
      <phone>+61734436996</phone>
      <fax>+61734437779</fax>
      <email>neil.finlayson@coridon.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>